法理视野下的行政权.docVIP

法 理 视 野 下 的 行 政 权 （讲课提纲） 广东省委党校法学部副主任、广东行政学院法学系硕士生导师、副教授 宋儒亮 一、问题与适应 行政执法人员滥用职权10个月损失6亿致死460人。 新华网北京 2003年12月10日电(记者，邬焕庆) 截至10月底，全国检察机关今年共查处行政执法人员滥用职权、玩忽职守犯罪案件1841件，这些案件造成经济损失6.5亿多元，致人死亡460人，重伤117人。 FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) The Food and Drug Administration today announced a series of important changes pertaining to the marketing of the non-steroidal anti-inflammatory class of drugs, including COX-2 selective and prescription and non-prescription (over-the-counter (OTC)) non-selective NSAID medications. A list of these products is available on the Internet at /cder/drug/infopage/cox2/default.htm. Todays actions protect and advance the health of the millions of Americans who rely on these drugs everyday, said Dr. Steven K. Galson, Acting Director of FDAs Center for Drug Evaluation and Research (CDER). FDA is providing the public information based on the latest available scientific data to guide the careful and appropriate use of these drugs aimed at maximizing their potential benefits and minimizing their risks. FDA has asked Pfizer, Inc. to withdraw Bextra (valdecoxib) from the market because the overall risk versus benefit profile for the drug is unfavorable. FDA has also asked Pfizer to include a boxed warning in the Celebrex (celecoxib) label. Pfizer has agreed to suspend sales and marketing of Bextra in the U.S., pending further discussions with the agency. Pfizer has agreed to work with FDA on the the boxed warning for Celebrex. FDA is asking manufacturers of all other prescription NSAIDs to revise their labels to include the same boxed warning highlighting the potential for increased risk of cardiovascular (CV) events and gastrointestinal (GI) bleeding associated with their use. Manufacturers of Celebrex and all other prescription NSAIDs will be asked to revise their labeling to include a Medication Guide for patients to help make them aware of the potential